Vizgen Announces Denial of 10x Genomics' Petition for Inter Partes Review of Vizgen-Licensed Patent Currently Asserted Against 10x's Xenium Platform [Yahoo! Finance]
10x Genomics, Inc. (TXG)
Last 10x genomics, inc. earnings: 2/18 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
spatial genomics information, is very pleased to announce that, on March 7, 2024, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied 10x Genomics Inc.'s petition to institute an Inter Partes Review proceeding (IPR) against U.S. Patent 11,098,303 B2 (‘303 Patent), which Vizgen licenses exclusively from Harvard University. This is the latest in a series of rulings against 10x in its aggressive attempts to weaponize patents to dominate the field through baseless litigation. In its decision denying the institution of an IPR of the ‘303 Patent, the PTAB noted that 10x's petition was deficient under the law and did not demonstrate " a reasonable likelihood that [10x] would prevail with respect to at least 1 of the claims challenged in the petition. " The denial of petition IPR2023-01299, which is available here , represents a crucial win for Vizgen. In C.A. No. 22-595-MFK, the parallel case in the U.S. District Court for the District o
Show less
Read more
Impact Snapshot
Event Time:
TXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXG alerts
High impacting 10x Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
TXG
News
- International Markets and 10x Genomics (TXG): A Deep Dive for Investors [Yahoo! Finance]Yahoo! Finance
- 10x Genomics to Present at the BofA Securities 2024 Healthcare ConferencePR Newswire
- 10x Genomics First Quarter 2024 Earnings: In Line With Expectations [Yahoo! Finance]Yahoo! Finance
- 10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at UBS Group AG from $52.00 to $30.00. They now have a "neutral" rating on the stock.MarketBeat
- 10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $30.00 to $26.00. They now have a "sell" rating on the stock.MarketBeat
TXG
Earnings
- 4/30/24 - Miss
TXG
Sec Filings
- 4/30/24 - Form 10-Q
- 4/30/24 - Form 8-K
- 4/26/24 - Form DEFA14A
- TXG's page on the SEC website